These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12383985)

  • 1. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: a randomised placebo-controlled trial.
    Mwinga A; Nunn A; Ngwira B; Chintu C; Warndorff D; Fine P; Darbyshire J; Zumla A;
    Lancet; 2002 Oct; 360(9339):1050-5. PubMed ID: 12383985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomised controlled trial. Durban Immunotherapy Trial Group.
    Lancet; 1999 Jul; 354(9173):116-9. PubMed ID: 10408487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis.
    Johnson JL; Nunn AJ; Fourie PB; Ormerod LP; Mugerwa RD; Mwinga A; Chintu C; Ngwira B; Onyebujoh P; Zumla A
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1348-54. PubMed ID: 15581204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa.
    Onyebujoh PC; Abdulmumini T; Robinson S; Rook GA; Stanford JL
    Respir Med; 1995 Mar; 89(3):199-207. PubMed ID: 7746913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia.
    Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn PP
    J Trop Med Hyg; 1995 Feb; 98(1):9-21. PubMed ID: 7861484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia.
    Mwinga A; Hosp M; Godfrey-Faussett P; Quigley M; Mwaba P; Mugala BN; Nyirenda O; Luo N; Pobee J; Elliott AM; McAdam KP; Porter JD
    AIDS; 1998 Dec; 12(18):2447-57. PubMed ID: 9875583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial.
    Peter JG; Zijenah LS; Chanda D; Clowes P; Lesosky M; Gina P; Mehta N; Calligaro G; Lombard CJ; Kadzirange G; Bandason T; Chansa A; Liusha N; Mangu C; Mtafya B; Msila H; Rachow A; Hoelscher M; Mwaba P; Theron G; Dheda K
    Lancet; 2016 Mar; 387(10024):1187-97. PubMed ID: 26970721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia.
    Elliott AM; Halwiindi B; Hayes RJ; Luo N; Mwinga AG; Tembo G; Machiels L; Steenbergen G; Pobee JO; Nunn P
    Trans R Soc Trop Med Hyg; 1995; 89(1):78-82. PubMed ID: 7747316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.
    Rangaka MX; Wilkinson RJ; Boulle A; Glynn JR; Fielding K; van Cutsem G; Wilkinson KA; Goliath R; Mathee S; Goemaere E; Maartens G
    Lancet; 2014 Aug; 384(9944):682-90. PubMed ID: 24835842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97.
    Mayo RE; Stanford JL
    Trans R Soc Trop Med Hyg; 2000; 94(5):563-8. PubMed ID: 11132390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population differences in death rates in HIV-positive patients with tuberculosis.
    Ciglenecki I; Glynn JR; Mwinga A; Ngwira B; Zumla A; Fine PE; Nunn A
    Int J Tuberc Lung Dis; 2007 Oct; 11(10):1121-8. PubMed ID: 17945070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer.
    Patel PM; Sim S; O'Donnell DO; Protheroe A; Beirne D; Stanley A; Tourani JM; Khayat D; Hancock B; Vasey P; Dalgleish A; Johnston C; Banks RE; Selby PJ
    Eur J Cancer; 2008 Jan; 44(2):216-23. PubMed ID: 18164612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa.
    Connolly C; Reid A; Davies G; Sturm W; McAdam KP; Wilkinson D
    AIDS; 1999 Aug; 13(12):1543-7. PubMed ID: 10465079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial.
    Daley P; Jagannathan V; John KR; Sarojini J; Latha A; Vieth R; Suzana S; Jeyaseelan L; Christopher DJ; Smieja M; Mathai D
    Lancet Infect Dis; 2015 May; 15(5):528-34. PubMed ID: 25863562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma.
    O'Brien ME; Saini A; Smith IE; Webb A; Gregory K; Mendes R; Ryan C; Priest K; Bromelow KV; Palmer RD; Tuckwell N; Kennard DA; Souberbielle BE
    Br J Cancer; 2000 Oct; 83(7):853-7. PubMed ID: 10970684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial.
    Gupta-Wright A; Corbett EL; van Oosterhout JJ; Wilson D; Grint D; Alufandika-Moyo M; Peters JA; Chiume L; Flach C; Lawn SD; Fielding K
    Lancet; 2018 Jul; 392(10144):292-301. PubMed ID: 30032978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV infection and sputum-culture conversion in patients diagnosed with Mycobacterium tuberculosis: a population-based study.
    Aliyu MH; Salihu HM; Ratard R
    Wien Klin Wochenschr; 2003 May; 115(10):340-6. PubMed ID: 12800448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological consequences of three doses of heat-killed Mycobacterium vaccae in the immunotherapy of tuberculosis.
    Dlugovitzky D; Fiorenza G; Farroni M; Bogue C; Stanford C; Stanford J
    Respir Med; 2006 Jun; 100(6):1079-87. PubMed ID: 16278080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.